Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

Objective. The 1980 American College of Rheuma-tology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although …

Objectives Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc)
and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, …

Objective To evaluate CAT‐192, a recombinant human antibody that neutralizes transforming
growth factor β1 (TGFβ1), in the treatment of early‐stage diffuse cutaneous systemic …

Objective To assess the safety and efficacy of rituximab in systemic sclerosis (SSc) in clinical
practice. Methods We performed a prospective study including patients with SSc from the …

Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder. Interstitial
lung disease (ILD) is common in SSc, occurring in 35–52% of patients and accounting for …

OBJECTIVE: Pulmonary hypertension (PH) is an ominous complication in patients with
scleroderma (systemic sclerosis, SSc). We compared noninvasive assessment of PH with …